Bringing the proteome into focus with single-molecule proteome and proteoform analysis
Monday, June 30, 2025 at 17:00 BST / 18:00 CEST / 12:00 EDT / 09:00 PDT
To date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds the promise to achieve improved dynamic range, reproducibility, and sensitivity in addition to enabling high-resolution evaluation of the distinct proteoforms created when protein isoforms are altered with specific combinations of post-translational modifications.
In this webinar, our experts will discuss how scalable, single-molecule protein analysis is transforming the field of proteomics, with a focus on its application in neurodegenerative disease research. Learn how researchers are now able to measure up to 2,048 tau proteoforms across model systems of Alzheimer’s disease, providing unprecedented insights into disease mechanisms and biomarker discovery.
Key learning objectives
- Discover the benefits of scalable, single-molecule protein analysis.
- Explore the impact of measuring up to 2,048 tau proteoforms across model systems of Alzheimer’s disease.
Who should attend?
- Researchers interested in novel proteomic techniques for broadscale proteome analysis.
- Researchers interested in exploring how protein isoforms and post-translational modifications combine to create distinct proteoforms with unique impacts, including those that impact tau and Alzheimer’s disease.
- Academic, biotech, and pharmaceutical professionals.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Parag Mallick obtained his Ph.D. in Chemistry and Biochemistry from UCLA, where he worked with Dr. David Eisenberg. He then completed his post-doctoral training with proteomics pioneer Ruedi Aebersold at the Institute for Systems Biology, where he worked on defining the biophysical origins of proteotypic peptides. He also did early work in proteogenomics and proteomics-based biomarker discovery. As an Associate Professor at Stanford, his lab uses a mix of quantitative proteomics, machine learning, and nanotechnology to perform systems biology studies of cancer initiation and progression that drive precision medicine approaches for cancer diagnosis and treatment. He is the founder and chief scientist of Nautilus Biotechnology, a company developing a large-scale, single-molecule platform for comprehensively quantifying the proteome.
Dr. Taylor Bertucci’s research focuses on building high-quality in vitro pluripotent stem cell (PSC)-derived models for disease modeling, drug screening, and regenerative medicine. She aims to advance these systems by developing scalable, robust platforms to recapitulate in vivo 3D microenvironments. Dr. Bertucci trained with Dr. Guohao Dai during her Ph.D. at Rensselaer Polytechnic Institute and then completed a postdoctoral fellowship at Northeastern University. At The Neural Stem Cell Institute, Dr. Bertucci has advanced sustained-release growth factor tools for cell culture by inventing DISC technology. Her research has also focused on establishing regionally-specific brain organoids as a robust, reproducible, and scalable platform across hPSC lines, facilitating better use of organoid models to study tauopathy.
Moderator
